8-K: Invivyd Reports Q4 and Full-Year 2024 Financial Results, Highlights PEMGARDA Revenue Growth

Invivyd announces a 48% increase in Q4 PEMGARDA revenue and progress in its next-generation COVID-19 antibody program.

Summary

• Invivyd reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Q4 2024 PEMGARDA net product revenue reached $13.8 million, a 48% increase over Q3 2024's $9.3 million.
• Full-year 2024 net product revenue totaled $25.4 million.
• The company's cash and cash equivalents at the end of 2024 were $69.3 million.
• Invivyd is targeting near-term profitability by the end of the first half of 2025.
• This profitability is expected to be achieved through revenue growth and reduced manufacturing expenses.
• The company announced positive Phase 1 clinical data for its next-generation program, VYD2311.
• VYD2311 showed an average 17-fold greater neutralization potency than pemivibart against contemporary SARS-CoV-2 variants.
• The FDA declined Invivyd's request to expand the emergency use authorization of PEMGARDA to include treatment of mild-to-moderate COVID-19 for immunocompromised patients with no alternative therapeutic options, and Invivyd has requested reconsideration.
• R&D expenses were $137.3 million for the year ended December 31, 2024, compared to $163.6 million for the comparable period in 2023.
• SG&A expenses were $63.4 million for the year ended December 31, 2024, compared to $49.1 million for the comparable period in 2023.
• Net loss was $169.9 million for the year ended December 31, 2024, compared to $198.6 million for the comparable period in 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the revenue growth and progress with VYD2311, but tempered by the net loss, declining cash reserves, and the FDA's decision regarding PEMGARDA's EUA expansion.

Positives

• PEMGARDA revenue is growing, indicating increased adoption and awareness.
• The company is targeting near-term profitability, suggesting improved financial management.
• VYD2311 shows promising Phase 1 clinical data and greater neutralization potency.
• Manufacturing expenses are expected to decrease in 2025, contributing to cost reductions.
• R&D expenses decreased year-over-year.
• Net loss decreased year-over-year.

Negatives

• The FDA declined to expand the EUA for PEMGARDA to include treatment of mild-to-moderate COVID-19 for immunocompromised patients.
• The company is still operating at a net loss of $169.9 million for the year ended December 31, 2024.
• Cash and cash equivalents decreased from $200.6 million at the end of 2023 to $69.3 million at the end of 2024.
• SG&A expenses increased year-over-year.

Risks

• The company's ability to achieve and sustain profitability is uncertain.
• Reliance on continued revenue growth of PEMGARDA and reduction of manufacturing expenses to achieve profitability.
• The FDA may not reconsider its decision regarding the expansion of PEMGARDA's EUA.
• Emergence of new SARS-CoV-2 variants could reduce the effectiveness of PEMGARDA and VYD2311.
• The company's cash reserves are decreasing, raising concerns about long-term funding.
• The company's forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the results described in or implied by the forward-looking statements.

Future Outlook

Invivyd is targeting near-term profitability by the end of the first half of 2025, driven by revenue growth and reduced manufacturing expenses. The company plans to continue advancing VYD2311 and raising awareness of PEMGARDA.

Management Comments

• 'We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, reflecting increased provider awareness and adoption,' said Bill Duke, Chief Financial Officer of Invivyd.
• 'We look forward to raising further awareness of PEMGARDA in the healthcare community and working to achieve near-term profitability,' said Bill Duke, Chief Financial Officer of Invivyd.
• 'With our impressive fourth quarter growth as our catalyst, we began 2025 with a newly transitioned, in-house sales force,' said Tim Lee, Chief Commercial Officer.

Industry Context

The announcement reflects the ongoing need for COVID-19 prevention and treatment options, particularly for vulnerable populations. The development of next-generation monoclonal antibodies like VYD2311 is crucial in addressing emerging variants and improving administration methods. The company's focus on profitability aligns with the broader industry trend of biopharmaceutical companies seeking sustainable financial models.

Comparison to Industry Standards

• Invivyd's PEMGARDA competes with other monoclonal antibody treatments and preventative measures for COVID-19, such as those previously offered by Regeneron and Eli Lilly, though many of these have lost effectiveness against newer variants.
• The 48% revenue growth in Q4 suggests a strong market uptake, but the overall revenue of $25.4 million is relatively modest compared to larger pharmaceutical companies in the infectious disease space.
• The focus on an intramuscular route of administration for VYD2311 mirrors efforts by other companies to develop more convenient and accessible antibody therapies.
• The company's cash position of $69.3 million is a key metric to watch, as it will determine their ability to fund ongoing research and commercialization efforts; this is lower than many comparably sized biopharmaceutical companies.

Related Party Transactions

• Related-party amounts included in accrued expenses were $1,274 for the year ended December 31, 2024 and $0 for the year ended December 31, 2023.
• Related-party amounts included in other non-current liability were $0 and $700 for the years ended December 31, 2024 and 2023, respectively.
• Related-party amounts included in cost of product revenue were $1,027 and $0 for the years ended December 31, 2024 and 2023, respectively.
• Related-party amounts included in research and development were $4,546 and $8,418 for the years ended December 31, 2024 and 2023, respectively.
• Related-party amounts included in acquired in-process research and development were $0 and $4,975 for the years ended December 31, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and progress with VYD2311, but concerned about the net loss and declining cash reserves.
• Healthcare providers and patients benefit from the availability of PEMGARDA and the potential of VYD2311 to address COVID-19.
• Employees are affected by the company's efforts to achieve profitability and advance its pipeline.

Next Steps

• Invivyd plans to continue raising awareness of PEMGARDA in the healthcare community.
• The company will continue advancing VYD2311 through clinical development.
• Invivyd will engage with the FDA to discuss next steps regarding the EUA for PEMGARDA.
• The company will focus on achieving near-term profitability.

Key Dates

Keywords

PEMGARDA, VYD2311, COVID-19, monoclonal antibody, Invivyd, financial results, revenue, profitability, EUA, neutralization, SARS-CoV-2